

Cited in: *EMBASE/Excerpta Medica, Oncology Information Service, Elsevier BIOBASE/Current Awareness in Biological Sciences; Current Contents/Clinical Medicine; SciSearch, Index Medicus/MEDLINE. Also covered in the abstract and citation database SCOPUS®. Full text available on ScienceDirect®.*

*Reviews*

- Immune checkpoint blockade in small cell lung cancer**  
R.Y. Tay (United Kingdom), D. Heigener, M. Reck (Germany), R. Califano (United Kingdom) 31
- Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)**  
A.C.Z. Gelatti (Brazil), A. Drilon (USA), F.C. Santini (Brazil) 113
- Original Research Articles*
- Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer**  
N. Guibert (France), G. Jones, J.F. Beeler, V. Plagnol, C. Morris (USA), J. Mourlanette, M. Delaunay, L. Keller, I. Rouquette, G. Favre, A. Pradines, J. Mazieres (France) 1
- A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer**  
H. Cheng, X.-J. Li, X.-J. Wang, Z.-W. Chen, R.-Q. Wang, H.-C. Zhong, T.-C. Wu, Q.-D. Cao (China) 7
- Survival in patients with malignant pleural effusion undergoing talc pleurodesis**  
M. Hassan (UK, Egypt), R.M. Mercer, N.A. Maskell, R. Asciale, D.J. McCracken, E.O. Bedawi (UK), H. Shaarawy, A. El-Ganady (Egypt), I. Psallidas, R.F. Miller, N.M. Rahman (UK) 14
- Let us not underestimate the long-term risk of SCLC after surgical resection of NSCLC**  
T. Leroy, E. Monnet, S. Guerzider, P. Jacoulet, B. De Bari, P.-E. Falcoz, M. Gagnet-Brun, J. Lahourcade, F. Alfreijjat, H. Almotlak, O. Adotevi, D. Pernet, J.-C. Polio, M. Desmarests, A.-S. Woronoff, V. Westeel (France) 23
- Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer**  
K. Teramoto, T. Igarashi, Y. Kataoka, M. Ishida, J. Hanaoka, H. Sumimoto, Y. Daigo (Japan) 56
- Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma**  
M. Takeda, Y. Ohe, H. Horinouchi, T. Hida, J. Shimizu, T. Seto, K. Nosaki, T. Kishimoto, I. Miyashita, M. Yamada, Y. Kaneko, C. Morimoto, K. Nakagawa (Japan) 64
- Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies**  
J.A. Hellyer, M.A. Gubens, K.M. Cunanan, S.K. Padda, M. Burns, A.J. Spittler, J.W. Riess, M. San Pedro-Salcedo, K.J. Ramchandran, J.W. Neal, H.A. Wakelee, P.J. Loehrer Sr (USA) 71
- Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy**  
M.-S. Hsieh, M.-W. Lin, Y.-H. Lee (Taiwan) 76
- Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice**  
Y. Jia, S. Zhao, T. Jiang, X. Li, C. Zhao, Y. Liu, R. Han, M. Qiao, S. Liu, C. Su, S. Ren, C. Zhou (PR China) 85

(Contents continued overleaf)



<b>Tumor-draining lymph nodes demonstrate a suppressive immunophenotype in patients with non-small cell lung cancer assessed by endobronchial ultrasound-guided transbronchial needle aspiration: A pilot study</b> V. Murthy, D.P. Katzman, J.-C.J. Tsay, J.L. Bessich, G.C. Michaud, S. Rafeq, J. Minehart, K. Mangalick, M.A.C. de Lafaille, C. Goparaju, H. Pass, D.H. Serman (United States)	94
<b>First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma</b> Z. Lin, S. Fu, Y. Zhou, X. Zhang, C. Chen, L.-n. He, H. Li, Y. Wang, T. Chen, L. Zhang, S. Hong (China)	100
<b>Consolidation-to-tumor ratio and tumor disappearance ratio are not independent prognostic factors for the patients with resected lung adenocarcinomas</b> H. Kim, J.M. Goo, Y.T. Kim, C.M. Park (Republic of Korea)	123
<b>Prognostic factors of acinar- or papillary-predominant adenocarcinoma of the lung</b> M. Kim, Y.S. Chung, K.A. Kim, H.S. Shim (Republic of Korea)	129
<b>A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer</b> B. Besse, F. Barlesi (France), I. Demedts (Belgium), J. Fuentes Pradera (Spain), G. Robinet, A. Gazzah (France), V. Soldatenkova (USA), B. Fridmott-Moller (Denmark), J.S. Kim (USA), J. Vansteenkiste (Belgium)	136
<b>Prognostic significance of blood and lymphatic vessel invasion in pathological stage IA lung adenocarcinoma in the 8th edition of the TNM classification</b> J. Samejima, T. Yokose, H. Ito, H. Nakayama, T. Nagashima, M. Suzuki, R. Hamanaka, K. Yamada, M. Masuda (Japan)	144
<b>Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study</b> C. Mehlman, J. Cadranet, G. Rousseau-Bussac, R. Lacave, A. Pujals, N. Girard, C. Callens, V. Gounant, N. Théou-Anton, S. Friard, J. Trédaniel, H. Blons, C. Dujon, B. Duchemann, P.O. Schischmanoff, T. Chinet, E. Giroux Leprieur (France)	149
<i>Short Communications</i>	
<b>Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer</b> G. Galli, A. De Toma, F. Pagani, G. Randon, B. Trevisan, A. Prelaj, R. Ferrara, C. Proto, D. Signorelli, M. Ganzinelli, N. Zilembo, F. de Braud, M.C. Garassino, G. Lo Russo (Italy)	38
<b>Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization</b> L. Kadouri, Y. Rottenberg, A. Zick, T. Hamburger (Israel), D. Lipson (United States), T. Peretz, H. Nechushtan (Israel)	48
<b>Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer</b> A. Yoshimura, T. Yamada, A. Miyagawa-Hayashino, Y. Sonobe, T. Imabayashi, T. Yamada, S. Okada, T. Shimamoto, Y. Chihara, M. Iwasaku, Y. Kaneko, J. Uchino, M. Inoue, E. Konishi, K. Takayama (Japan)	108
<i>Case Reports</i>	
<b>The clinical responses of <i>TNIP2-ALK</i> fusion variants to crizotinib in <i>ALK</i>-rearranged lung adenocarcinoma</b> T. Feng, Z. Chen, J. Gu, Y. Wang, J. Zhang, L. Min (China)	19
<b>Spread of hyperplastic pulmonary neuroendocrine cells into air spaces (S.H.I.P.M.E.N.T.S): A proof for artifact</b> G. Pelosi, F. Nesa, D. Taietti, S.P. Servillo, N. Papanikolaou, M. Zompatori, A. Meroni, S. Harari, M. Incarbone (Italy)	43
<b>Identification of the <i>BRAF</i> V600E mutation in a patient with sclerosing pneumocytoma: A case report</b> G. Jiang, M. Zhang, Q. Tan, S. Lin, Y. Zeng, C. Liu, R. Chen, J. Zhou (China)	52
<i>Correspondence</i>	
<b>Comment on the article titled “Impact of <i>KRAS</i> mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes”</b> J. Wen, J. Chen, M. Fan (China)	157
<b>Response to comment on “Impact of <i>KRAS</i> mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes”</b> J.V. Aredo, S.K. Padda, C.A. Kunder, S.S. Han, J.W. Neal, J.B. Shrager, H.A. Wakelee (USA)	159